Statin therapy and multiple sclerosis disability in a population-based cohort

Multiple Sclerosis Journal

Volumn 18, Issue 3, 2012, Pages 358-363

  Soldán, M Mateo Paz ^a   Pittock, Sean J ^a   Weigand, Stephen D ^a   Yawn, Barbara P ^b   Rodriguez, Moses ^a  

^a MAYO CLINIC   (United States)

^b OLMSTED MEDICAL CENTER   (United States)

Author keywords

disability; HMG CoA reductase inhibitors; multiple sclerosis; population based; statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; PERIPHERAL VASCULAR DISEASE; REVIEW;

EID: 84857880414     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511421920     Document Type: Review

References (23)

1. Compston A. The basis for treatment in multiple sclerosis. Acta Neurol Scand Suppl. 2006 ; 183: 41-47
2. Sadeghi MM, Tiglio A, Sadigh K, et al. Inhibition of interferon-gamma- mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation. 2001 ; 71: 1262-1268 (Pubitemid 32507145)
3. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002 ; 420: 78-84 (Pubitemid 35291443)
4. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001 ; 7: 687-692 (Pubitemid 32588024)
5. Johnson-Anuna LN, Eckert GP, Keller JH, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther. 2005 ; 312: 786-793 (Pubitemid 40189580)
6. Johnson-Anuna LN, Eckert GP, Franke C, Igbavboa U, Muller WE, Wood WG.. Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 ; 101: 77-86 (Pubitemid 46426484)
7. Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP.. Simvastatin regulates oligodendroglial process dynamics and survival. Glia. 2007 ; 55: 130-143 (Pubitemid 46036460)
8. Foote AK, Blakemore WF. Inflammation stimulates remyelination in areas of chronic demyelination. Brain. 2005 ; 128: 528-539 (Pubitemid 40380188)
9. Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004 ; 24: 806-815 (Pubitemid 38620856)
10. Jurevics H, Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem. 1995 ; 64: 895-901
11. Saher G, Brugger B, Lappe-Siefke C, et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci. 2005 ; 8: 468-475 (Pubitemid 41007564)
12. Maier O, De Jonge J, Nomden A, Hoekstra D, Baron W. Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes. Glia. 2009 ; 57: 402-413
13. Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett. 1999 ; 269: 71-74 (Pubitemid 29335415)
14. Miron VE, Zehntner SP, Kuhlmann T, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009 ; 174: 1880-1890
15. Sena A, Pedrosa R, Graca Morais M. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol. 2003 ; 250: 754-755 (Pubitemid 36718367)
16. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004 ; 363: 1607-1608 (Pubitemid 38625664)
17. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One. 2008 ; 3: e1928
18. Togha M, Karvigh SA, Nabavi M, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010 ; 16: 848-854
19. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008 ; 71: 1390-1395
20. Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology. 2004 ; 62: 601-606 (Pubitemid 38252802)
21. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231 (Pubitemid 13158528)
22. Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci. 2010 ; 25: 1-21
23. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010 ; 74: 1041-1047